Author

K. Hidaka

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Biochemistry· 1 Pharmacology & Toxicology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Organism:bacteria (other)· 1 Research Focus:cell signaling & trafficking· 1 Research Focus:host-pathogen & immune response· 1 Organism:mouse· 1 Assay:protein structure· 1

Frequent Co-Authors

C. J. Stubenrauch· 1 shared C. T. Webb· 1 shared D. J. Maloney· 1 shared E. M. Germany· 1 shared H.-H. Shen· 1 shared K. Imai· 1 shared K. Matsumoto· 1 shared K. S. Tan· 1 shared

Activity by Year

2020-2021 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 24 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperBiochemistry

C. J. Stubenrauch

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Dual Recognition of Multiple Signals in Bacterial Outer Membrane Proteins Enhance Assembly and Maintain Membrane Integrity

E. M. Germany, N. Thewasano, K. Imai, Y. Maruno, R. S. Bamert, C. J. Stubenrauch, R. A. Dunstan, Y. Ding, Y. Nakajima, X. Lai, C. T. Webb, K. Hidaka, K. S. Tan, H.-H. Shen, T. Lithgow, T. Shiota

The paper identifies an additional signal in bacterial outer membrane proteins that enhances assembly efficiency and maintains membrane integrity through interaction with BamD.

bioRxiv · Oct 29, 2021Biochemistry

Ameliorative effect of a quinazoline-based bromodomain inhibitor, CN210, on experimentally-induced Crohn's disease-like murine ileitis via inhibition of inflammatory cytokine expression

T. Noguchi, K. Hidaka, S. Kobayashi, K. Matsumoto, M. Yoshioka, S.-M. Yang, D. J. Maloney, S. Kato

This study shows that CN210, a quinazoline-based BET inhibitor, reduces inflammation in a murine model of Crohn's disease by inhibiting inflammatory cytokine expression and NF-κB/MAP kinase pathways.

bioRxiv · Jan 24, 2020Pharmacology & Toxicology